Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from PTC Therapeutics ( (PTCT) ) is now available.
PTC Therapeutics held its Annual Meeting on June 17, 2025, where stockholders elected three Class III directors to serve until the 2028 annual meeting. Additionally, the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. The stockholders also approved a non-binding advisory proposal on named executive officer compensation.
The most recent analyst rating on (PTCT) stock is a Buy with a $63.00 price target. To see the full list of analyst forecasts on PTC Therapeutics stock, see the PTCT Stock Forecast page.
Spark’s Take on PTCT Stock
According to Spark, TipRanks’ AI Analyst, PTCT is a Outperform.
PTC Therapeutics receives a strong score, driven by promising financial performance improvements and optimistic earnings call guidance. However, mixed technical analysis and ongoing regulatory challenges temper the outlook. The company’s strategic product launches and financial management provide a foundation for potential growth, despite some risks.
To see Spark’s full report on PTCT stock, click here.
More about PTC Therapeutics
Average Trading Volume: 1,222,815
Technical Sentiment Signal: Buy
Current Market Cap: $4.11B
Find detailed analytics on PTCT stock on TipRanks’ Stock Analysis page.